<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2693">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819700</url>
  </required_header>
  <id_info>
    <org_study_id>PI11-PR-GODEFROY-2</org_study_id>
    <nct_id>NCT02819700</nct_id>
  </id_info>
  <brief_title>Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)</brief_title>
  <acronym>ISDC</acronym>
  <official_title>Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      Behavioural disorders are very common right from the initial stage of dementia and contribute&#xD;
      to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their&#xD;
      prevalence and their diagnostic importance, as they often constitute the initial symptoms of&#xD;
      Frontotemporal Dementia (FTD), Semantic Dementia (SD) and Huntington's disease (HD) and they&#xD;
      are classically more frequent in vascular dementia (VaD) than in Alzheimer's disease (AD).&#xD;
      The presence of these disorders at the stage of Mild Cognitive Impairment (MCI) has only been&#xD;
      partially evaluated and would increase the risk of progression to dementia. These classical&#xD;
      data are based on non-standardized assessments and non-validated diagnostic criteria. The&#xD;
      Groupe de Reflexion pour l'Evaluation des Fonctions EXécutives (GREFEX) has developed a&#xD;
      standardized assessment tool for behavioural dysexecutive disorders, the Behavioural&#xD;
      Dysexecutive Syndrome Inventory (BDSI) and has validated diagnostic criteria for this&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 29, 2013</start_date>
  <completion_date type="Actual">January 28, 2018</completion_date>
  <primary_completion_date type="Actual">January 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ISDC (Behavioural Dysexecutive Syndrome Inventory)</measure>
    <time_frame>Day 0</time_frame>
    <description>Behavioural Dysexecutive Syndrome Inventory</description>
  </primary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <condition>Huntington Disease</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Semantic Dementia</condition>
  <condition>Dementia, Vascular</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>prevalence of behavioural dysexecutive syndrome</intervention_name>
    <description>Behavioural Dysexecutive Syndrome Inventory (ISDC)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        French-speaking subjects between the ages of 40 and 85 years with an MMSE score &gt; 15/30,&#xD;
        followed for AD or MCI or VaD or FTD or SD or HD will be selected by their neurologist&#xD;
        during a routine memory assessment visit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Support to the consultation memory for a neurological disease ( frontotemporal&#xD;
             dementia , vascular dementia , Alzheimer's disease , mild cognitive disorder,&#xD;
             Huntington's disease ( with genetic diagnosis confirmed : number of CAG triplets &gt; 36&#xD;
             symptomatic : UHDRS score ≥5 ) with MMS &gt; 15&#xD;
&#xD;
          -  Age 40 to 85 years&#xD;
&#xD;
          -  French&#xD;
&#xD;
          -  Informing reliable&#xD;
&#xD;
          -  Agreeing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other disease disturbing behavior ( current depressive syndrome ,&#xD;
             schizophrenia, psychosis , past psychiatric disorders requiring a stay &gt; 2 days in a&#xD;
             specialized environment ) or cognition (mental retardation , illiteracy , respiratory&#xD;
             failure, kidney , liver , heart ) or preventing the realization of the tests (&#xD;
             perceptual or motor deficit ) intrecérébrale pacing therapy or stem cell transplant ,&#xD;
             patient protected ( under supervision or guardianship ) , pregnant and / or&#xD;
             breastfeeding and lack of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier GODEFROY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>behavioural disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

